Takeda Pharmaceutical Co. Ltd.

Products

Category

Product

Brand

Description

Gastrointestinal Therapeutics and Diagnostics (PHM046D)

Entyvio (vedolizumab)		A bowel anti-inflammatory drug. It is a humanized monoclonal antibody (mAb) drug for moderate to severe ulcerative colitis and Crohn’s disease.
Takecab/ Vocinti (vonoprazan fumarate)		Potassium-competitive acid blocker (P-CAB). A treatment for acid-related diseases. Takecab was launched in Japan in 2015. As of December 2023, it was not FDA-approved.
Gattex/ Revestive (teduglutide [rDNA origin])		Glucagon-like peptide-2 (GLP-2) analog. A treatment for patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex/ Revestive has been launched in the U.S., Europe, and Japan, and it has adult and pediatric indications.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment